Frizzled-7 as a potential therapeutic target in colorectal cancer

Koji Ueno1, Mikako Hiura, Yutaka Suehiro

  • 1Department of Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Japan.

Neoplasia (New York, N.Y.)
|July 2, 2008
PubMed

Insights

Frizzled-7 (FZD7) activates the Wnt pathway in colorectal cancer (CRC) cells with APC or CTNNB1 mutations. FZD7-siRNA reduces CRC cell growth and invasion, suggesting FZD7 as a therapeutic target for CRC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Colorectal cancer (CRC) often involves mutations in APC or CTNNB1, activating the Wnt signaling pathway.
  • The role of Wnt receptors, specifically frizzled-7 (FZD7), in CRC with these mutations is not fully understood.
  • Identifying novel therapeutic targets is crucial for treating sporadic CRCs.

Purpose of the Study:

  • To investigate the function of FZD7 in the canonical Wnt signaling pathway of CRC cells with APC or CTNNB1 mutations.
  • To evaluate FZD7 as a potential therapeutic target for sporadic CRCs.
  • To assess the impact of FZD7 modulation on CRC cell behavior.

Main Methods:

  • Real-time PCR to determine FZD gene family expression in colon cancer cell lines and primary CRC tissues.
  • TOPflash assay to evaluate Wnt signaling pathway activation.
  • MTS and matrigel assays to assess cell growth and invasion, respectively.
  • Transfection with FZD7 cDNA and FZD7-siRNA to modulate FZD7 activity.

Main Results:

  • FZD7 mRNA was predominantly expressed in six colon cancer cell lines harboring APC or CTNNB1 mutations.
  • FZD7 transfection increased Tcf transcriptional activity (1.5- to 24.3-fold) and Wnt target gene expression (1.5- to 3.4-fold).
  • FZD7-siRNA significantly reduced Tcf transcriptional activity (20% to 80%), cell viability, and invasion in HCT-116 cells.

Conclusions:

  • FZD7 activates the canonical Wnt pathway in colon cancer cells, even with APC or CTNNB1 mutations.
  • FZD7 plays a significant role in CRC cell growth and invasion.
  • FZD7-siRNA demonstrates potential as a therapeutic reagent for colorectal cancer.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...